New Drugs for the Treatment of Diabetes

  • Inzucchi S
  • McGuire D
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs.

Cite

CITATION STYLE

APA

Inzucchi, S. E., & McGuire, D. K. (2008). New Drugs for the Treatment of Diabetes. Circulation, 117(4), 574–584. https://doi.org/10.1161/circulationaha.107.735795

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free